Olanzapine in combination with aripiprazole for treatment of schizophrenia in breast cancer patients
| Autor: | V.V. Sushko |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Olanzapine
medicine.medical_specialty Positive and Negative Syndrome Scale business.industry medicine.medical_treatment Hyperprolactinaemia medicine.disease Psychiatry and Mental health Breast cancer Schizophrenia Internal medicine medicine Aripiprazole Antipsychotic business Adverse effect medicine.drug |
| Zdroj: | European Psychiatry. 23:S169-S170 |
| ISSN: | 0924-9338 |
| DOI: | 10.1016/j.eurpsy.2008.01.969 |
| Popis: | Background:Olanzapine and aripiprazole is effective, safe, and well tolerated for the positive and negative symptoms in schizophrenia. Hyperprolactinaemia is a frequent side-effect in the use of atypical antipsychotics. The endocrine and sexual side effects related to hyperprolactinaemia significantly impair in breast cancer patients.Methods:The effect combination of a low doses olanzapine and aripiprazole were examined in a sample of 21 breast cancer patients who had the schizophrenia and olanzapine-induced hyperprolactinaemia. They were randomly assigned to experimental or control groups. They were interviewed by psychiatrists and tested using Positive and Negative Syndrome Scale (PANSS) at baseline and follow-up visits. Plasma prolactin level was assessed at baseline and at the end of the study. The patients of control group received olanzapine as their sole antipsychotic agent at a maximum dose of 5 mg once daily. The patients’ experimental group received olanzapine at a maximum dose of 5 mg once daily in combination with aripiprazole at a maximum dose of 10 mg once daily.Results:No differences between initial groups were identified. The results of our study suggest that after three weeks of schizophrenia treatment, 81,8% patients from the experimental group and 40% from the control group showed significant clinical improvement. At the end of weeks 3, serum prolactin levels were normalized (7.9+/-4.7 micrograms/L) in patients’ experimental group.Conclusion:These data show that combination of a low doses olanzapine and aripiprazole for treatment schizophrenia in breast cancer patients may result in enhanced antipsychotic efficacy while reducing adverse effects including olanzapine-induced hyperprolactinaemia. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|